|
|
|
|
| It’s impossible to attend an event on the future of RNA therapeutics without hearing about the challenges we’re facing with targeted RNA-LNP delivery. In this final Advancing RNA Live discussion of 2024, we sit down with three LNP experts to parse out the current opportunities and unknowns facing the development of next-generation LNPs. Secure your spot today! Registration is free thanks to the support of Helix Biotech. |
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | Subjectivity and hearsay will no doubt play a big role in how we approach the FDA's Platform Designation guidance moving forward, and I daresay these hard to mitigate factors will complicate our relationship with this designation in the future. |
|
|
|
By Jack (Jie) Huang M.D., Ph.D., CSTEAM Biotechnology | An overview of considerations for the design and development, quality control and characterization, regulatory submissions, and future directions for oligonucleotides. |
|
|
|
As the panelists of this Advancing RNA LIVE discussion argue, there are several big limitations we face in implementing QBD today for RNA development. |
|
|
|
By Ioanna Deni, BioPlan Associates Inc. | BioPlan Associates' latest manufacturing survey found signs of a maturing market and strong demand for innovation upstream and downstream. |
|
|
|
| Mechanisms Of LNP-Mediated mRNA Delivery | Article | By Michael Nguyen, Ph.D., Helix Biotech | Explore the details supporting LNP-mediated mRNA delivery, as well as the challenges facing mRNA based therapeutics in the future. |
|
|
|
|
| Integrated Solutions For Advanced Therapies | White Paper | Catalent | The right CDMO offering integrated services can ease increasingly common CGT manufacturing problems such as scale, raw material access, viral vector production, and quality requirements. |
|
|
|
.png){kind=logo}
